Overview

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Status:
Withdrawn
Trial end date:
2018-07-17
Target enrollment:
Participant gender:
Summary
This is a study to determine the efficacy, safety and clinical benefit (how well the drugs works), of the pharmaceutical compositions in Nasal Spray NST-4G for the treatment of brain tumors( Recurrent Glioblastoma, Gliosarcoma,Anaplastic Gliomas, Previously Treated). All drugs target the inhibition of the growth factors and neo-angiogenesis as one the main reasons for the growth of the tumor. The purpose of the Nasal Spray NST-4G study is to determine the safety and tolerability in order to establish the best dose level to be used in future studies.
Phase:
Phase 1
Details
Lead Sponsor:
Center Trials & Treatment
Treatments:
Axitinib
Sunitinib